INT200443

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.60
First Reported 2005
Last Reported 2010
Negated 6
Speculated 0
Reported most in Body
Documents 27
Total Number 27
Disease Relevance 22.46
Pain Relevance 3.22

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (AES)
Anatomy Link Frequency
upper respiratory tract 3
digits 1
skin 1
reproductive tract 1
AES (Homo sapiens)
Pain Link Frequency Relevance Heat
withdrawal 18 99.84 Very High Very High Very High
aspirin 1 99.56 Very High Very High Very High
headache 29 99.52 Very High Very High Very High
cINOD 81 99.38 Very High Very High Very High
Arthritis 55 99.12 Very High Very High Very High
pruritus 9 98.32 Very High Very High Very High
psoriasis 135 96.96 Very High Very High Very High
rheumatoid arthritis 99 95.88 Very High Very High Very High
Pain 73 86.96 High High
methotrexate 122 86.64 High High
Disease Link Frequency Relevance Heat
Arthropathy 486 100.00 Very High Very High Very High
Reprotox - General 1 32 99.76 Very High Very High Very High
Headache 29 99.52 Very High Very High Very High
Common Cold 5 99.26 Very High Very High Very High
Hypoactive Sexual Desire Disorder 8 99.20 Very High Very High Very High
Arthritis 37 99.12 Very High Very High Very High
Reprotox - General 2 9 98.64 Very High Very High Very High
Weight Gain 24 98.56 Very High Very High Very High
Urinary Tract Infection 2 98.48 Very High Very High Very High
Toxicity 95 98.46 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In addition, topical NSAIDs, like all NSAIDs, have a black box warning for increased risk of cardiovascular events and serious GI AEs (10).
Positive_regulation (increased) of AEs associated with cinod
1) Confidence 0.60 Published 2010 Journal International Journal of Clinical Practice Section Body Doc Link PMC2984542 Disease Relevance 0.69 Pain Relevance 0.59
In both of these studies (Fig. 2), there was no overall increase in the incidence of arthropathy AEs over time.
Neg (no) Positive_regulation (increase) of AEs associated with arthropathy
2) Confidence 0.58 Published 2006 Journal Arch Dermatol Res Section Body Doc Link PMC1705535 Disease Relevance 0.87 Pain Relevance 0
Data from two long-term studies showed that there was no increase in the incidence of arthropathy AEs over time in patients treated with efalizumab for up to 36 months.
Neg (no) Positive_regulation (increase) of AEs associated with arthropathy
3) Confidence 0.58 Published 2006 Journal Arch Dermatol Res Section Abstract Doc Link PMC1705535 Disease Relevance 0.58 Pain Relevance 0
Efalizumab does not appear to increase the risk of arthropathy AEs compared with placebo.



Positive_regulation (increase) of AEs associated with arthropathy
4) Confidence 0.42 Published 2006 Journal Arch Dermatol Res Section Abstract Doc Link PMC1705535 Disease Relevance 0.61 Pain Relevance 0
Arthropathy AEs and clinical response to efalizumab
Positive_regulation (response) of AEs associated with arthropathy
5) Confidence 0.42 Published 2006 Journal Arch Dermatol Res Section Body Doc Link PMC1705535 Disease Relevance 1.29 Pain Relevance 0
The GELA (Groupe d'Etude des Lymphomes de l'Adulte) group, which performed the study, did not find any overall difference in the rate of all-cause AEs between those patients receiving CHOP and those receiving CHOP plus rituximab.
Positive_regulation (cause) of AEs
6) Confidence 0.42 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC2833973 Disease Relevance 0.73 Pain Relevance 0
The majority of patients experienced AEs during the first infusion, and incidence declined with subsequent infusions.
Positive_regulation (experienced) of AEs
7) Confidence 0.42 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC2833973 Disease Relevance 1.97 Pain Relevance 0.23
Although this scenario is likely to occur infrequently in clinical practice, these data show that if a patient needs to stop (e.g., during pregnancy) and then restart treatment, there appears to be no increased risk of arthropathy AEs.
Neg (no) Positive_regulation (increased) of AEs associated with arthropathy
8) Confidence 0.39 Published 2006 Journal Arch Dermatol Res Section Body Doc Link PMC1705535 Disease Relevance 1.03 Pain Relevance 0.23
The improvement seen with maintenance therapy also appears to have been achieved without increases in AEs.
Neg (without) Positive_regulation (increases) of AEs
9) Confidence 0.39 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC2833973 Disease Relevance 0.67 Pain Relevance 0
The most frequently occurring AEs with the reproductive tract were genital pruritus, vaginal candidiasis, vaginal discharge, bacterial vaginitis, and vulvovaginitis.
Positive_regulation (occurring) of AEs in reproductive tract associated with reprotox - general 2, bacterial vaginosis and pruritus
10) Confidence 0.36 Published 2007 Journal PLoS ONE Section Body Doc Link PMC2129116 Disease Relevance 1.22 Pain Relevance 0.34
Neither group showed an increase in reactogenicity for local and general AEs with increasing number of doses.
Positive_regulation (increase) of AEs
11) Confidence 0.32 Published 2010 Journal Journal of Korean Medical Science Section Body Doc Link PMC2908791 Disease Relevance 1.49 Pain Relevance 0.13
While higher doses may produce further benefit, this strategy is mitigated by a dose-related increase in some AEs, such as QTc prolongation, EPS and weight gain.
Positive_regulation (increase) of AEs associated with weight gain
12) Confidence 0.31 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2656329 Disease Relevance 0.86 Pain Relevance 0
In a study of discontinuation patterns in patients receiving IFN beta, patients who stopped therapy as a result of AEs did so after a median period of 13 months on treatment, whereas those who discontinued as a result of treatment failure (defined as non-reduction in pre-treatment relapse rate and/or sustained increase of Expanded Disability Status Scale score of ?
Positive_regulation (result) of AEs associated with recurrence
13) Confidence 0.30 Published 2010 Journal Patient Prefer Adherence Section Body Doc Link PMC2819898 Disease Relevance 0.41 Pain Relevance 0.20
Nasopharyngitis, arthralgia, diarrhoea, lower and upper respiratory tract infections and headache were the most commonly reported AEs in both the PRM and placebo-treated groups during both treatment (3-week and 26 weeks extension) periods (Table 9).
Positive_regulation (reported) of AEs in upper respiratory tract associated with common cold, arthralgia, diarrhoea, nasopharyngitis and headache
14) Confidence 0.23 Published 2010 Journal BMC Med Section Body Doc Link PMC2933606 Disease Relevance 0.68 Pain Relevance 0.10
This may suggest that the frequency of prolactin-related AEs associated with paliperidone ER therapy is underestimated.


Positive_regulation (frequency) of AEs
15) Confidence 0.22 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2656329 Disease Relevance 0.18 Pain Relevance 0
Potential prolactin-related AEs were impotence and abnormal sexual function with placebo; and nonpuerperal lactation and decreased libido with paliperidone ER 12 mg.
Positive_regulation (Potential) of AEs associated with hypoactive sexual desire disorder and reprotox - general 1
16) Confidence 0.22 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2656329 Disease Relevance 0.80 Pain Relevance 0
Potential prolactin-related AEs were reported in ?
Positive_regulation (Potential) of AEs
17) Confidence 0.22 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2656329 Disease Relevance 0.52 Pain Relevance 0
For example, the injection site of the therapy can be varied to decrease the likelihood of local skin reactions, butterfly needles can be used, and patients should be properly trained to ensure that SC, rather than intradermal, infusions are achieved; patients should also be educated about the most common AEs that might be expected [38].
Positive_regulation (educated) of AEs in skin
18) Confidence 0.19 Published 2008 Journal Int J Hematol Section Body Doc Link PMC2516545 Disease Relevance 1.61 Pain Relevance 0.31
However, source data verification of 10% of patients did not suggest that a significant number of AEs were missed, with a similar occurrence of events reported for patients with different end digits of their patient number (Chi-squared test, p = 0.8).
Positive_regulation (number) of AEs in digits
19) Confidence 0.15 Published 2009 Journal Patient Saf Surg Section Body Doc Link PMC2711964 Disease Relevance 0.13 Pain Relevance 0
Patients in the placebo group in cycle 1 had a higher incidence of AEs, SAEs, and severe SAEs compared to the XM02 and Neupogen™ groups.
Positive_regulation (incidence) of AEs
20) Confidence 0.09 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2628928 Disease Relevance 1.21 Pain Relevance 0.08

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox